Date: 2012-11-05
Type of information: Initiation of preclinical development
phase: 1
Announcement:
Company: Amgen (USA - CA)
Product: AMG 232
Action
mechanism: inhibitor of MDM2.
Disease: advanced solid tumors, glioblastoma, multiple myeloma
Therapeutic area: Cancer - Oncology
Country: France, The Netherlands, USA
Trial
details: This first in human, open-label, sequential dose escalation and expansion study is evaluating AMG 232 in adult subjects with advanced solid tumors or multiple myeloma. (NCT01723020)
Latest news:
